As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

Sarepta Therapeutics refused a FDA request to halt shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.

Sarepta has not yet announced a plan to address the FDA’s concerns about its drug, but said it plans to meet with the FDA before the end of the year, according to STAT. Sarepta’s stock price ...

Sarepta disclosed the first patient death — a 16-year-old boy — in March. Both occurred from acute liver failure, a side effect that has been seen with other gene therapies.

Hearing that a second boy with Duchenne had died from liver failure after receiving Elevidys was a shock, said Kameron Lawson, speaking to STAT on Sunday night from their home in Stockton, Calif.

Sarepta Therapeutics Inc's shares fell more than 6% on Thursday as Stat News reported that the U.S. health regulator's staff were inclined to reject the company's gene therapy which is currently ...